Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Science / Health/  Covid vaccine: Moderna targets emergency approval in December
BackBack

Covid vaccine: Moderna targets emergency approval in December

In July, Moderna started a 30,000-person study in the US to test its covid vaccine candidate

A Moderna Inc. sign is displayed on a shelf during clinical trials for a Covid-19 vaccine at Research Centers of AmericaPremium
A Moderna Inc. sign is displayed on a shelf during clinical trials for a Covid-19 vaccine at Research Centers of America

US-based Moderna expects interim results of its covid vaccine trials next month. And if the company gets positive interim results from the large clinical trial, the US government could authorize emergency use of the company’s experimental Covid-19 vaccine in December, its chief executive said.

Speaking during The Wall Street Journal’s annual Tech Live conference on Monday, Chief Executive Stephane Bancel said if sufficient interim results from the study takes longer to get, government authorization of the vaccine may not occur until early next year.

US-based Moderna has one of the leading Covid-19 vaccines in development, along with a vaccine co-developed by Pfizer Inc and BioNTech.

Last week, Pfizer Inc had said that it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing. "So let me be clear, assuming positive data, Pfizer will apply for Emergency Authorization Use in the U.S. soon after the safety milestone is achieved in the third week of November," Pfizer Chief Executive Albert Bourla said.

The US government's Operation Warp Speed program has spent billions of dollars on development of vaccines and treatments.

In July, Moderna started a 30,000-person study in the US to test its vaccine candidate.

In the trial, half of the study subjects receive the vaccine and half receive a placebo, and researchers then count how many get symptomatic Covid-19.

That first analysis is likely to occur in November, but “it’s hard to predict exactly which week because it depends on the cases, the number of people getting sick," Moderna CEO Bancel said.

Moderna had earlier this month said that it will soon apply for real-time reviews of its experimental COVID-19 vaccine in Europe, days after the EU health regulator launched rolling reviews of shots from its rivals.

The drug developer said it was in talks with European countries and would submit the same data it plans to submit to the U.S. Food and Drug Administration for authorization.

The European Medicines Agency this month launched real-time reviews of COVID-19 vaccines being developed by U.S. drugmaker Pfizer and Germany's BioNTech, following a similar announcement for AstraZeneca's.

(With Agency Inputs)

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 20 Oct 2020, 09:26 AM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App